^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CDK6 inhibitor

    Related drugs:
    2d
    Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC (clinicaltrials.gov)
    P2, N=14, Active, not recruiting, Case Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=29 --> 14
    Enrollment closed • Enrollment change
    |
    Verzenio (abemaciclib)
    2d
    Lucentis Plus Tagolimumab in PD-L1+, HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitors (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Lucentis (ranibizumab) • Simponi (golimumab)
    9d
    FN-1501 Synergistically Enhances Almonertinib Efficacy in EGFR-TKI-Resistant Lung Adenocarcinoma through Ferroptosis Induction. (PubMed, Anticancer Agents Med Chem)
    FN-1501 exhibits significant antitumor activity and, when combined with Alm, effectively reverses EGFR-TKI resistance by inducing ferroptosis, highlighting its potential for clinical application.
    Journal
    |
    NCOA4 (Nuclear Receptor Coactivator 4)
    |
    Ameile (aumolertinib) • FN-1501
    10d
    OP-1250-002: A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, Olema Pharmaceuticals, Inc. | Trial completion date: Jul 2025 --> Mar 2026 | Trial primary completion date: Jan 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    Ibrance (palbociclib) • palazestrant (OP-1250)
    15d
    A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    fulvestrant • Jingzhuda (entinostat)
    16d
    Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd
    New P2 trial • Tumor mutational burden
    |
    hydroxyurea • flonoltinib
    16d
    (CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Weill Medical College of Cornell University | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Verzenio (abemaciclib)
    21d
    NCI-2020-05682: Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors (clinicaltrials.gov)
    P=N/A, N=700, Recruiting, Roswell Park Cancer Institute | Trial completion date: Jul 2030 --> Jul 2035
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    23d
    AIM-BRIGHT: Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer. (clinicaltrials.gov)
    P2, N=105, Not yet recruiting, University of California, San Diego
    New P2 trial
    |
    fulvestrant
    24d
    PIKALO-2: A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) (clinicaltrials.gov)
    P3, N=920, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane • LY4064809
    25d
    INAVO123: A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=450, Recruiting, Hoffmann-La Roche | Trial primary completion date: Jan 2028 --> May 2032
    Trial primary completion date
    |
    letrozole • Itovebi (inavolisib)
    25d
    Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial (clinicaltrials.gov)
    P2, N=42, Not yet recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Sep 2031 --> Apr 2031 | Initiation date: Sep 2025 --> Apr 2026 | Trial primary completion date: Sep 2030 --> Apr 2030
    Trial completion date • Trial initiation date • Trial primary completion date • Minimal residual disease
    |
    Verzenio (abemaciclib) • Inluriyo (imlunestrant)